Vaccines, blood, antisera, toxins and cultures in   Singapore

Exports In 2023, Singapore exported $10.9B in Vaccines, blood, antisera, toxins and cultures, making it the 8th largest exporter of Vaccines, blood, antisera, toxins and cultures in the world. At the same year, Vaccines, blood, antisera, toxins and cultures was the 4th most exported product in Singapore. The main destination of Vaccines, blood, antisera, toxins and cultures exports from Singapore are: United States ($6.15B), China ($2.13B), Switzerland ($773M), Germany ($337M), and Ireland ($282M).

The fastest growing export markets for Vaccines, blood, antisera, toxins and cultures of Singapore between 2022 and 2023 were United States ($3.49B), China ($2.12B), and Switzerland ($199M).

Imports In 2023, Singapore imported $1.43B in Vaccines, blood, antisera, toxins and cultures, becoming the 26th largest importer of Vaccines, blood, antisera, toxins and cultures in the world. At the same year, Vaccines, blood, antisera, toxins and cultures was the 43rd most imported product in Singapore. Singapore imports Vaccines, blood, antisera, toxins and cultures primarily from: United States ($310M), Ireland ($296M), Spain ($210M), Germany ($130M), and Belgium ($107M).

The fastest growing import markets in Vaccines, blood, antisera, toxins and cultures for Singapore between 2022 and 2023 were Ireland ($150M), United States ($32.8M), and Germany ($19M).